Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33801
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Reynolds, Gemma K | - |
dc.contributor.author | Sim, Beatrice | - |
dc.contributor.author | Spelman, Tim | - |
dc.contributor.author | Thomas, Ashmitha | - |
dc.contributor.author | Longhitano, Anthony | - |
dc.contributor.author | Anderson, Mary Ann | - |
dc.contributor.author | Thursky, Karin | - |
dc.contributor.author | Slavin, Monica | - |
dc.contributor.author | Teh, Benjamin W | - |
dc.date | 2023 | - |
dc.date.accessioned | 2023-09-27T05:36:37Z | - |
dc.date.available | 2023-09-27T05:36:37Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.citation | Critical Reviews in Oncology/Hematology 2023-12; 192 | en_US |
dc.identifier.issn | 1879-0461 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/33801 | - |
dc.description.abstract | A registered (PROSPERO - CRD42022346462) systematic review and meta-analysis was conducted of all-grade infections amongst adult patients receiving CAR-T therapy for haematological malignancy. Meta-analysis of pooled incidence, using random effects model, was conducted. Cochran's Q test examined heterogeneity. 2678 patients across 33 studies were included in the primary outcome. Forty-percent of patients (95% CI: 0.33 - 0.48) experienced an infection of any grade. Twenty-five percent of infection events (95% CI: 0.16 - 0.34) were severe. Late infections were as common as early infections (IRR = 0.86, 95% CI: 0.38 - 1.98). All-grade infections, bacterial and viral infections were highest in myeloma patients at 57%, 37% and 28% respectively. Patients with NHL more commonly experienced late infections. Pooled rate of invasive candidiasis/yeast infections was 2% in studies utilizing anti-yeast prophylaxis. This review identified a high rate of all-grade infections, moderate rate of severe infections, and myeloma as a high-risk haematological group. | en_US |
dc.language.iso | eng | - |
dc.subject | CAR-T | en_US |
dc.subject | Cellular therapies | en_US |
dc.subject | Infections | en_US |
dc.subject | Lymphoma | en_US |
dc.subject | Myeloma | en_US |
dc.title | Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Critical Reviews in Oncology/Hematology | en_US |
dc.identifier.affiliation | Dpartment of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Department of Infectious Diseases, Austin Health, Melbourne, Victoria. | en_US |
dc.identifier.affiliation | National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. | en_US |
dc.identifier.affiliation | Infectious Diseases | en_US |
dc.identifier.affiliation | Department of Infectious Diseases, Barwon Health, Melbourne, Victoria. | en_US |
dc.identifier.affiliation | Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria. | en_US |
dc.identifier.doi | 10.1016/j.critrevonc.2023.104134 | en_US |
dc.type.content | Text | en_US |
dc.identifier.pubmedid | 37739146 | - |
dc.description.startpage | 104134 | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.